Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SH-08
- Development stage
- Unknown
- Lead developer
- Nanjing Sanhome Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SH-08 is a potent and highly selective small molecule inhibitor of Janus kinase 1 (JAK1), developed by Nanjing Sanhome Pharmaceutical for the treatment of autoimmune and inflammatory conditions. By selectively blocking JAK1, the drug inhibits the signaling of various pro-inflammatory cytokines (such as IL-6, IFN-gamma, and IL-15) through the JAK-STAT pathway, while potentially avoiding the side effects associated with the inhibition of other JAK isoforms like JAK2 (erythropoiesis) and JAK3 (immune cell development). SH-08 is currently being evaluated in Phase 2 clinical trials for rheumatoid arthritis and is also under investigation for other indications, including atopic dermatitis.
02
Targets
Beyond the preview
Go deeper on SH-08.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SH-08.